Table 2.

The influence of PPC on PFS (6 month) after chemotherapy.

Patient Characteristics	Cases	Univariate analysis			Multivariate analysis
		HR	95% CI	p	HR	95% CI	p
Gender
Male	55	1			1
Female	43	0.579	0.330–1.433	0.437	0.411	0.412–1.667	0.352
Age
<55	47	1			1
≥55	51	0.545	0.354–1.228	0.552	0.575	0.335–1.454	0.645
Stage
IVa	19	1			1
IVb	79	0.736	0.338–1.996	0.586	0.866	0.657–2.012	0.725
Lauren type
Diffuse	60	1			1
intestinal	38	1.323	0.746–2.364	0.833	1.401	0.619–2.116	0.443
tumour location
Gastric body	13	1			1
Gastric cardia	35	1.146	0.615–3.889	0.559	1.409	0.684–4.002	0.601
Pyloru&Antrum	50	1.332	0.656–4.332	0.651	1.432	0.766–4.449	0.697
Chemotherapy
SOX	68	1			1
XELOX	30	0.835	0.622–2.992	0.756	0.778	0.654–3.112	0.783
PPC
YES	46	1				1
NO	52	0.471	0.221–0.915	0.047	0.512	0.298–1.045	0.053

Abbreviations: HR, hazard ratio; CI, confidence interval.